HC Wainwright Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $46.00

Dyne Therapeutics (NASDAQ:DYN) had its price objective decreased by analysts at HC Wainwright from $55.00 to $46.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 237.99% from the company’s current price. HC Wainwright also issued estimates for Dyne Therapeutics’ Q1 2025 earnings at ($0.90) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.91) EPS and FY2029 earnings at $1.56 EPS.

Several other analysts have also issued reports on DYN. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $48.64.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $13.61 on Friday. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -3.82 and a beta of 1.11. The business has a 50 day moving average of $16.98 and a 200 day moving average of $27.61. Dyne Therapeutics has a 1-year low of $12.87 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, sell-side analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Activity at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,387 shares of company stock worth $142,789 over the last quarter. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its holdings in shares of Dyne Therapeutics by 0.3% during the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after buying an additional 698 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after buying an additional 709 shares in the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after buying an additional 721 shares in the last quarter. KBC Group NV boosted its holdings in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after buying an additional 751 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.